CardioScale

Company Overview

Snapshot

Founded in February 2012 by Maoz Ben - Ari and Uri Gabbay, CardioScale operates with 1–10 employees. The company has raised $100K across one funding round. In October 2019, CardioScale's Cardiovascular Reserve Index (CVRI) calculator received CE Mark approval.

Business overview

CardioScale develops solutions for on-site deterioration prediction in trauma victims, aiming to improve triage and treatment prioritization. Its core technology includes a proprietary algorithm and the portable cuff monitor, DTR8, which measures vital signs and a cardiovascular reserve index (CVRI) to detect shock and pre-shock deterioration. The company serves the health tech and life sciences sectors, with applications in medical devices, digital healthcare, and patient remote monitoring, targeting healthcare providers, patients, and military and civil defense organizations.

Strategic signal

In October 2019, CardioScale's Cardiovascular Reserve Index (CVRI) calculator received CE Mark approval. This regulatory milestone is significant as it validates the device's compliance with European health, safety, and environmental protection standards, enabling market access and commercialization within the European Economic Area. For investors, this signals a critical step towards product readiness and market entry for a technology designed to enhance trauma care.

Company Intelligence Q&A

When was CardioScale founded?

CardioScale was founded in February 2012.

What significant regulatory approval did CardioScale receive?

In October 2019, CardioScale's Cardiovascular Reserve Index (CVRI) calculator received CE Mark approval, signifying compliance with European standards.

Which competition did CardioScale win recognition in?

In June 2018, CardioScale was among the winners announced in the Counter-Terrorism Startup Competition.

What is the status of CardioScale's operations?

CardioScale is currently non-active and ceased to operate in November 2025.